Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS)
Cancer Causes & Control · 2023
DOI: 10.1007/s10552-023-01675-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Causes & Control, 2023. Verfasst von Maira A Castañeda-Avila und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, 368 Plantation Street, A6-1065O, Worceste…. Hauptthemen laut MEDLINE: Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: Monoclonal gammopathy of undetermined significance (MGUS) is the precursor of multiple myeloma. This qualitative study described patient (n = 14) experiences and healthcare providers' (n = 8) opinions and practices concerning care for patients with MGUS in the US. METHODS: Semi-structured, in-depth interviews were analyzed using thematic analysis. RESULTS: We identified six overarching themes related to the care pathway for patients with MGUS: (1) Process of MGUS diagnosis, (2) Providers' explanations, (3) Patients' understanding, (4) Impact of the diagnosis, (5) Follow-up/management, and (6) Factors influencing healthcare utilization. Patients demonstrated a basic understanding of MGUS. However, some patients felt anxiety around the diagnosis, which may affect other aspects of their lives. Non-hematologist providers report having less MGUS-specific knowledge. Older age, high-risk MGUS, and insurance coverage/healthcare costs influenced healthcare utilization. CONCLUSION: Patients with MGUS may have difficulty processing this premalignant diagnosis. Non-hematologist providers may have gaps in knowledge around specific care for patients with MGUS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, 368 Plantation Street, A6-1065O, Worcester, MA, 01605, USA. maira.castanedaavila@umassmed.edu.
- Meyers Health Care Institute, A Joint Endeavor of the University of Massachusetts Chan Medical School, Fallon Health, and Reliant Medical Group, Worcester, MA, USA.
- Division of Health Systems Science, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, 368 Plantation Street, A6-1065O, Worcester, MA, 01605, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Castañeda-Avila, M. A., Mazor, K. M., Lapane, K. L., & Epstein, M. M. (2023). Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS). Cancer Causes & Control. https://doi.org/10.1007/s10552-023-01675-1
Vancouver
Castañeda-Avila MA, Mazor KM, Lapane KL, Epstein MM. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS). Cancer Causes & Control. 2023. doi:10.1007/s10552-023-01675-1
BibTeX
@article{CastaedaAvila2023,
author = {Castañeda-Avila, Maira A and Mazor, Kathleen M and Lapane, Kate L and Epstein, Mara M},
title = {Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS)},
journal = {Cancer Causes & Control},
year = {2023},
doi = {10.1007/s10552-023-01675-1}
}
EUVIMED